02 June 2015: Meta-Analysis
Effect of Proliferator-Activated Receptor-γ Pro12Ala Polymorphism on Colorectal Cancer Risk: A Meta-Analysis
Zhijiang Wei ABCDEF , Guoda Han BCDF , Xiyong Bai CD
DOI: 10.12659/MSM.892849
Med Sci Monit 2015; 21:1611-1616
Abstract
BACKGROUND: The association between peroxisome proliferators-activated receptor γ (PPARγ) Pro12Ala polymorphism and colorectal cancer (CRC) risk is still controversial. A meta-analysis was performed.
MATERIAL AND METHODS: We conducted a literature search using PubMed, EMBASE, and Cochran databases. The pooled odds ratio (OR) with 95% confidence intervals (CIs) were calculated. Fixed-effects and random-effects models were used. Dominant model, recessive model, and additive model were used in this meta-analysis.
RESULTS: Fifteen studies including 13575 cases and 17085 controls were included in our meta-analysis. Result of this meta-analysis found that PPARγ Pro12Ala polymorphism was significantly associated with a reduced risk of CRC (OR=0.90; 95% CI 0.83–0.98; P=0.01). No significant association was found between PPARγ Pro12Ala polymorphism and CRC risk in Asians (OR=0.80; 95% CI 0.60–1.09; P=0.15). However, PPARγ Pro12Ala polymorphism was significantly associated with a reduced risk of CRC in Caucasians (OR=0.91; 95% CI 0.83–0.99; P=0.03). When stratified analysis was performed by CRC site, no positive association was found between PPARγ Pro12Ala polymorphism and rectal cancer (OR=0.95; 95% CI 0.74–1.22; P=0.71). However, a reduced risk of colon cancer was observed (OR=0.85; 95% CI 0.76–0.94; P=0.002).
CONCLUSIONS: In summary, this study suggests that PPARγ Pro12Ala polymorphism was a protective factor of CRC.
Keywords: Asian Continental Ancestry Group - genetics, Colorectal Neoplasms - genetics, European Continental Ancestry Group - genetics, Genetic Association Studies, Genetic Predisposition to Disease - genetics, Models, Genetic, Mutation, Missense - genetics, Odds Ratio, PPAR gamma - genetics, Polymorphism, Genetic - genetics
Background
Colorectal cancer (CRC) is a common digestive tumor; the incidence of CRC is just lower than gastric and esophageal cancer. More than one million new cases of CRC were diagnosed globally each year [1]. CRC is becoming a very urgent public health concern, especially in the developed countries. In USA, the incidence rate and mortality rate of CRC ranked third among all tumors in both men and women [2]. Body mass index, height, smoking status, and alcohol use have been reported to be associated with CRC risk [3]. However, the pathogenesis of CRC is still uncertain. Identification of related genetic variants could elucidate mechanisms underlying this disease.
Peroxisome proliferators-activated receptors (PPAR), which have PPARα, PPARβ/δ and PPARγ, are members of the nuclear receptor superfamily of ligand-activated transcription factors [4]. Due to its association with many human cancers such as colon, thyroid, breast, and prostate, PPARγ has been suggested to be an attractive target for cancer therapy [4]. Although the PPARγ nuclear receptor pathway was involved in cancer development, it might appear to have both oncogenic and tumor suppressor functions. Sarraf et al. showed that ligand activation of PPARγ in colon cancer cells could cause a considerable reduction in linear and clonogenic growth, increase expression of carcinoembryonic antigen, and the reversal of many gene expression events specifically associated with colon cancer [5]. However, Saez et al. suggested that PPARγ activation may provide a molecular link between a high-fat diet and increased risk of CRC [6].
A common polymorphism in the PPARγ, CCA®GCA, causing a Pro®Ala substitution at codon 12 (Pro12Ala), has been reported. The Pro12Ala polymorphism has been suggested to be associated with decreased receptor activity, lower body mass index, and improved insulin sensitivity [7]. The Pro®Ala change might cause a conformational change in the PPARγ protein, and thus affect its activity. Several studies have reported the association between PPARγ Pro12Ala polymorphism and CRC risk [8–22]. However, the results were still equivocal. Recently, a meta-analysis with nine studies found that this polymorphism was not associated with CRC risk [23]. However, six case-control studies were published and not all studies supported that result. Therefore, we performed a meta-analysis of all eligible studies to evaluate the association between PPARγ Pro12Ala polymorphism and CRC risk.
Material and Methods
MATERIAL:
We conducted a literature search using PubMed, EMBASE, and Cochran databases. The following terms were used: “colorectal neoplasms” or “colorectal cancer”) and (“PPARγ” or “peroxisome proliferators-activated receptor γ”). The last search was updated on December, 2014. All searched studies were retrieved and only published studies with full-text articles were included. In duplicate samples, only the largest study was used in this research.
INCLUSION/EXCLUSION CRITERIA:
The inclusion criteria was as follows: (1) a case-control study or a cohort study; (2) the study evaluated the association between PPARγ Pro12Ala polymorphism and CRC risk; (3) the PPARγ Pro12Ala genotypes were provided.
The exclusion criteria were as follows: (1) animal studies; (2) not relevant to CRC or PPARγ; (3) reviews or abstracts; (4) not offer enough data.
DATA EXTRACTION:
Two authors extracted the following data: first author, year, race, sample size, and genotype distribution. The disagreements were resolved by consensus.
STATISTICAL ANALYSIS:
Statistical analysis was all conducted using Stata software 11.0 (StataCorp, College Station, Texas, USA). HWE test in healthy control group was conducted using χ2 test. Odds ratio (OR) with a 95% confidence interval (CI) was presented for dichotomous data, and significance level was 0.05. Dominant model, recessive model, and additive model were used in this meta-analysis.
Results
ELIGIBLE STUDIES:
Figure 1 shows the study selection procedure. Based on the inclusion and exclusion criteria, 15 studies including 13575 cases and 17085 controls were included in our meta-analysis. Only three studies were performed in Asian populations, while other studies were performed in Caucasian populations. The characteristics of the included studies are listed in Table 1.
QUANTITATIVE SYNTHESIS:
Result of this meta-analysis suggest that PPARγ Pro12Ala polymorphism was significantly associated with a reduced risk of CRC in dominant genetic model (OR=0.90; 95% CI 0.83–0.98; P=0.01; Figure 2). No significant association was found between PPARγ Pro12Ala polymorphism and CRC risk in Asians (OR=0.80; 95% CI 0.60–1.09; P=0.15). However, PPARγ Pro12Ala polymorphism was significantly associated with a reduced risk of CRC in Caucasians (OR=0.91; 95% CI 0.83–0.99; P=0.03). When stratified analysis was performed by CRC site, no positive association was found between PPARγ Pro12Ala polymorphism and rectal cancer (OR=0.95; 95% CI 0.74–1.22; P=0.71). However, a reduced risk of colon cancer was observed (OR=0.85; 95% CI 0.76–0.94; P=0.002). Results of other genetic models are listed in Table 2.
To evaluate the reliability of the results, we conducted cumulative meta-analysis by pooling the data, and each time one study was added. The results showed that the pooled ORs tended to be stable (Figure 3). We also performed the one-way sensitivity analysis by omitting studies one at a time. We found that any single study did not influence the pooled OR, suggesting that the results of this meta-analysis were robust (Figure 4). Moreover, no significant publication bias was found by funnel plot (Figure 5) and Egger’s test (P=0.12)
Discussion
PPARγ Pro12Ala polymorphism has been reported to be associated with breast cancer, gastric cancer, and inflammatory bowel disease [24–26]. Lu et al. suggested that PPARγ Pro12Ala polymorphism was not associated with CRC risk [23]. However, a previous meta-analysis found that PPARγ Pro12Ala polymorphism might be a protective factor for CRC [26]. Thus, we did this update meta-analysis to find the association between PPARγ Pro12Ala polymorphism and CRC risk. We found that PPARγ Pro12Ala polymorphism was significant associated with CRC risk, suggesting that PPARγ Ala allele carriers had reduced CRC risk compared to PPARγ Pro allele carriers. Furthermore, we found that this effect was only existed in Caucasians but not in Asians, suggesting a possible influence among different genetic backgrounds and environmental exposures, but these were only studies with Asians. More studies with Asians are needed to further investigate the association between PPARγ Pro12Ala polymorphism and CRC risk. Results from this meta-analysis found that PPARγ Pro12Ala polymorphism was only associated with colon cancer. No significant association was found between PPARγ Pro12Ala polymorphism and rectal cancer. It has been suggested that PPARγ activity was higher in the distal colon [27]; it is possible that the Ala/Ala+Pro/Ala genotypes had the greatest effect in the segment of the colon with the least PPARγ activity [28].
Ligands for the PPARγ have proven to be effective in preclinical models of CRC. Tanaka and coworkers indicated that administration of the PPARγ ligand troglitazone significantly reduces the number of aberrant crypt foci (ACF) lesions [29]. Aires et al. found that the combination of resveratrol with a PPARγ agonist could be a promising pharmacological approach for treatment of CRC [30]. Thus, PPARγ agonists combined with other chemotherapy drugs or other targeted therapies are worth pursuing in the treatment of CRC [31–36].
There were some limitations in this meta-analysis. First, the number of included studies was moderate. Therefore, the results could be influenced by random error. Second, CRC is a multifactorial disease, but the interactions among gene-environment and gene-gene were not considered in this meta-analysis. Third, other factors such as gender or diet habit may participate in the progression of CRC. However, we did not conduct subgroup analysis by these factors due to limited data.
Conclusions
In summary, this study suggested that PPARγ Pro12Ala polymorphism was a protective factor of CRC.
References
1. Cunningham D, Atkin W, Lenz HJ, Colorectal cancer: Lancet, 2010; 375(9719); 1030-47, pmid: 20304247
2. Siegel R, Naishadham D, Jemal A, Cancer statistics, 2012: Cancer J Clin, 2012; 62(1); 10-29
3. Hutter CM, Chang-Claude J, Slattery ML: Cancer Res, 2012; 72(8); 2036-44, pmid: 22367214
4. Michalik L, Desvergne B, Wahli W, Peroxisome-proliferator-activated receptors and cancers: complex stories: Nat Rev Cancer, 2004; 4(1); 61-70, pmid: 14708026
5. Sarraf P, Mueller E, Jones D, Differentiation and reversal of malignant changes in colon cancer through PPARgamma: Nat Med, 1998; 4(9); 1046-52, pmid: 9734398
6. Saez E, Tontonoz P, Nelson MC, Activators of the nuclear receptor PPARgamma enhance colon polyp formation: Nat Med, 1998; 4(9); 1058-61, pmid: 9734400
7. Deeb SS, Fajas L, Nemoto M, A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity: Nat Genet, 1998; 20(3); 284-87, pmid: 9806549
8. Landi S, Moreno V, Gioia-Patricola LBellvitge Colorectal Cancer Study Group, Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer: Cancer Res, 2003; 63; 3560-66, pmid: 12839942
9. Jiang J, Gajalakshmi V, Wang J, Influence of the C161T but not Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma on colorectal cancer in an Indian population: Cancer Sci, 2005; 96; 507-12, pmid: 16108832
10. McGreavey LE, Turner F, Smith GColorectal Cancer Study Group, No evidence that polymorphisms in CYP2C8, CYP2C9, UGT1A6, PPARdelta and PPARgamma act as modifiers of the protective effect of regular NSAID use on the risk of colorectal carcinoma: Pharmacogenet Genomics, 2005; 15; 713-21, pmid: 16141797
11. Murtaugh MA, Ma KN, Caan BJ, Interactions of peroxisome proliferator-activated receptor γamma} and diet in etiology of colorectal cancer: Cancer Epidemiol Biomarkers Prev, 2005; 14; 1224-29, pmid: 15894676
12. Koh WP, Yuan JM, Van Den Berg D, Peroxisome proliferator-activated receptor (PPAR) gamma gene polymorphisms and colorectal cancer risk among Chinese in Singapore: Carcinogenesis, 2006; 27; 1797-802, pmid: 16513680
13. Kuriki K, Hirose K, Matsuo K, Meat, milk, saturated fatty acids, the Pro12Ala and C161T polymorphisms of the PPARgamma gene and colorectal cancer risk in Japanese: Cancer Sci, 2006; 97; 1226-35, pmid: 16965392
14. Slattery ML, Curtin K, Wolff R, PPARgamma and colon and rectal cancer: associations with specific tumor mutations, aspirin, ibuprofen and insulin-related genes (United States): Cancer Causes Control, 2006; 17; 239-49, pmid: 16489531
15. Theodoropoulos G, Papaconstantinou I, Felekouras E, Relation between common polymorphisms in genes related to inflammatory response and colorectal cancer: World J Gastroenterol, 2006; 12; 5037-43, pmid: 16937502
16. Vogel U, Christensen J, Dybdahl M, Prospective study of interaction between alcohol, NSAID use and polymorphisms in genes involved in the inflammatory response in relation to risk of colorectal cancer: Mutat Res, 2007; 624; 88-100, pmid: 17544013
17. Küry S, Buecher B, Robiou-du-Pont S, Low-penetrance alleles predisposing to sporadic colorectal cancers: a French case-controlled genetic association study: BMC Cancer, 2008; 8; 326, pmid: 18992148
18. Slattery ML, Wolff RK, Curtin K, Colon tumor mutations and epigenetic changes associated with genetic polymorphism: insight into disease pathways: Mutat Res, 2009; 660; 12-21, pmid: 18992263
19. Hawken SJ, Greenwood CM, Hudson TJ, The utility and predictive value of combinations of low penetrance genes for screening and risk prediction of colorectal cancer: Hum Genet, 2010; 128; 89-101, pmid: 20437058
20. Abulí A, Fernández-Rozadilla C, Alonso-Espinaco VGastrointestinal Oncology Group of the Spanish Gastroenterological Association, Case-control study for colorectal cancer genetic susceptibility in EPICOLON: previously identified variants and mucins: BMC Cancer, 2011; 11; 339, pmid: 21819567
21. Crous-Bou M, Rennert G, Salazar R, Genetic polymorphisms in fatty acid metabolism genes and colorectal cancer: Mutagenesis, 2012; 27(2); 169-76, pmid: 22294764
22. Sainz J, Rudolph A, Hoffmeister M, Effect of type 2 diabetes predisposing genetic variants on colorectal cancer risk: J Clin Endocrinol Metab, 2012; 97; E845-51, pmid: 22419714
23. Lu YL, Li GL, Huang HL, Peroxisome proliferator-activated receptor-gamma 34C>G polymorphism and colorectal cancer risk: a meta-analysis: World J Gastroenterol, 2010; 16; 2170-75, pmid: 20440859
24. Zhang ZF, Yang N, Zhao G, Association between the Pro12Ala polymorphism of peroxisome proliferator-activated receptor gamma 2 and inflammatory bowel disease: a meta-analysis: PLoS One, 2012; 7(1); e30551, pmid: 22276212
25. Mao Q, Guo H, Gao L, Peroxisome proliferator-activated receptor γ2 Pro12Ala (rs1801282) polymorphism and breast cancer susceptibility: a meta-analysis: Mol Med Rep, 2013; 8(6); 1773-78, pmid: 24141935
26. Xu W, Li Y, Wang X, PPARgamma polymorphisms and cancer risk: a meta-analysis involving 32,138 subjects: Oncol Rep, 2010; 24(2); 579-85, pmid: 20596649
27. Lefebvre M, Paulweber B, Fajas L, Peroxisome proliferator-activated receptor gamma is induced during differentiation of colon epithelium cells: J Endocrinol, 1999; 162(3); 331-40, pmid: 10467224
28. Rangwala SM, Rhoades B, Shapiro JS, Genetic modulation of PPARgamma phosphorylation regulates insulin sensitivity: Dev Cell, 2003; 5(4); 657-63, pmid: 14536066
29. Tanaka T, Kohno H, Yoshitani S, Ligands for peroxisome proliferator-activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats: Cancer Res, 2001; 61(6); 2424-28, pmid: 11289109
30. Aires V, Brassart B, Carlier A, A role for peroxisome proliferator-activated receptor gamma in resveratrol-induced colon cancer cell apoptosis: Mol Nutr Food Res, 2014; 58(9); 1785-94, pmid: 24975132
31. Sümbül AT, Dişel U, Sezgin N, Can serial monitoring of serum Vascular Endothelial Growth Factor (VEGF), Nitric Oxide (NO), and Angiotensin II (ANGII) levels have predictive role during Bevacizumab treatment?: Med Sci Monit, 2014; 20; 428-33, pmid: 24632679
32. Süren D, Yıldırım M, Demirpençe Ö, The role of high mobility group box 1 (HMGB1) in colorectal cancer: Med Sci Monit, 2014; 20; 530-37, pmid: 24681824
33. Süren D, Yıldırım M, Kaya V, Loss of tight junction proteins (Claudin 1, 4, and 7) correlates with aggressive behavior in colorectal carcinoma: Med Sci Monit, 2014; 20; 1255-62, pmid: 25038829
34. Gao L, Bai L, Nan Qz, Activation of Rho GTPase Cdc42 promotes adhesion and invasion in colorectal cancer cells: Med Sci Monit Basic Res, 2013; 19; 201-7, pmid: 23884297
35. Płachetka A, Adamek B, Strzelczyk JK, 8-hydroxy-2′-deoxyguanosine in colorectal adenocarcinoma – is it a result of oxidative stress?: Med Sci Monit, 2013; 19; 690-95, pmid: 23963109
36. Han DP, Zhu QL, Cui JT, Polo-like kinase 1 is overexpressed in colorectal cancer and participates in the migration and invasion of colorectal cancer cells: Med Sci Monit, 2012; 18(6); BR237-46, pmid: 22648245
In Press
Clinical Research
Institutional and Regional Variations in Access to Clinical Trials and Next-Generation Sequencing in Turkis...Med Sci Monit In Press; DOI: 10.12659/MSM.951027
Clinical Research
Low-Intensity Blood Flow-Restricted Multi-Joint Exercise Improves Muscle Function in Patients With Patellof...Med Sci Monit In Press; DOI: 10.12659/MSM.950516
Review article
Musculoskeletal Ultrasound and MRI in the Evaluation of Chemotherapy-Induced Peripheral Neuropathy: A ReviewMed Sci Monit In Press; DOI: 10.12659/MSM.951283
Clinical Research
Sensory Processing, Dissociation, and Affective Symptoms in Misophonia: A Cross-Sectional Study of 35 AdultsMed Sci Monit In Press; DOI: 10.12659/MSM.950938
Most Viewed Current Articles
17 Jan 2024 : Review article 10,187,196
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
13 Nov 2021 : Clinical Research 3,708,487
Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...DOI :10.12659/MSM.932788
Med Sci Monit 2021; 27:e932788
14 Dec 2022 : Clinical Research 2,341,643
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research 706,524
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387